Expression of Peroxisome Proliferator-activated Receptor α and β in Peripheral Blood Mononuclear Cells of Non-vavular Hypertensive Atrial Fibrillation Patients

DENG Xiao-ming, LUO Xiao-jia, CHEN Xiao-ping, HE Sen, LI Long-xin, WAN Li-yan, PENG Yong

Abstract

To determine the mRNA expressions of PPARα and PPARβ in peripheral blood mononuclear cells of non-vavular hypertensive atrial fibrillation (AF) patients and elucidate its possible role in the pathogenesis of AF. Methods Peripheral blood samples were collected from 103 patients with hypertensive AF (persistent AF:55, paroxysmal AF:48) and 50 age-adjusted hypertension patients without AF. The mRNA expressions of PPARα, PPARβ, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in monocytes were detected by using a Real time polymerase chain reaction. The concentrations of high sensitive C-reactive protein (CRP) and interleukin-1 (IL-1) were measured by immunoenzymetric method. Results The PPARα mRNA expression level was persistently decreased in hypertensive non-AF group, paroxysmal AF group, and persistent AF group (1.34±0.17,1.09±0.23,0.85±0.22), while the difference was statistically significant (P<0.001; respectively). TNF-α mRNA,IL-6 mRNA,CRP and IL-1 persistently increased in hypertensive non-AF group, paroxysmal AF group, persistent AF group, also the difference was statistically significant (P<0.001; respectively). The difference of PPARβ mRNA was not statistically significant between non-AF group, paroxysmal AF group and persistent AF group. Left atrial diameter (LAD) was in positive correlation with CRP, IL-1, IL-6 mRNA and TNF-α mRNA (P<0.05). PPARα mRNA level was in negative correlation with CRP,IL-1,IL-6 mRNA and TNF-α mRNA, the correlation coefficient was -0.519, -0.532, -0.491 and -0.528, respectively (P<0.05). Conclusion In hypertensive patients with AF, increased inflammatory cytokines were associated with atrial remodeling and lead to the development of atrial fibrillation; PPARα was negatively correlated with these inflammatory cytokines and may play a vital role in the process of atrial fibrillation development.

 

Keywords: Non-valvular atrial fibrillation, Hypertension, PPARα, PPARβ

 

Full Text:

PDF


References


Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med, 1994; 154(13) ; 1449-1457.

Stewart S, Hart CL, Hole DJ, etui. A population-based study of the long-term risks associated with atrial fibrillation; 20-year follow-up of the Renfrew/Paisley study. Am J Med.2002; 113 (5):359-364.

Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein. interleukin-6, and TNF-a) and essential hypertension. J Hum Hypertens,2005 ; 19(2) : 149-154.

Aviles RJ . Martin DO, Apperson-Hansen С,et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003; 108 (24);3006-3010.

Sesso HD, Wang L, Buring JE, et al. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension,2007;49(2):304-310.

Devchand PR, Keller H, Peters JM,et al. The PPARalpha - leukotriene B4 pathway to inflammation control. Nature, 1996; 384(6604): 39-43.

Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem.1998; 273(49):32833-32841.

Hourton D, Delerive P, Stankova J, et al. Oxidized low- density lipoprotein and peroxisome-proliferator-activated receptor alpha downregulate platelet-activating- factor receptor expression in human macrophages. Biochem J , 2001; 354 ( Pt 1):225-232.

Chen X, Bing Z, He J, et al. Downregulation of peroxisome proliferator-activated receptor-y expression in hypertensive atrial. Clin Cardiol,2009;32(6):337-345.

Vaziri SM, Larson MG, Benjamin EJ. et al. Echocardiographic predictors of nonrheumatic atrial fibrillation; The Framingham Heart Study. Circulation, 1994 ; 89( 2); 724- 730.

Vranka I, Penz P, Dukat A. Atrial conduction delay and its association with left atrial dimension, left atrial pressure and left ventricular diastolic dysfunction in patients at risk of atrial fibrillation. Exp Clin Cardiol,2007; 12(4); 197-201.

Psychari SN. Apostolou TS, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol,2005;95(6) :764-767.

Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res, 2002; 54 (2):361-379.

Schotten U, Ausma J, Stellbrink C, et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation,2001; 103(5):691 -698.

Marx N, Kehrle B, Kohlhammer К,et al. PPAR activators as antiinflammatory mediators in human T lymphocytes; implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res, 2002; 90(6): 703-710.

Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C- reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation.2001; 103(21):2531-2534.


Refbacks

  • There are currently no refbacks.